<code id='7F7E359275'></code><style id='7F7E359275'></style>
      • <acronym id='7F7E359275'></acronym>
      <center id='7F7E359275'><center id='7F7E359275'><tfoot id='7F7E359275'></tfoot></center><abbr id='7F7E359275'><dir id='7F7E359275'><tfoot id='7F7E359275'></tfoot><noframes id='7F7E359275'>
      • <optgroup id='7F7E359275'><strike id='7F7E359275'><sup id='7F7E359275'></sup></strike><code id='7F7E359275'></code></optgroup>
        5. <b id='7F7E359275'><label id='7F7E359275'><select id='7F7E359275'><dt id='7F7E359275'><span id='7F7E359275'></span></dt></select></label></b><u id='7F7E359275'></u>
          <i id='7F7E359275'><strike id='7F7E359275'><tt id='7F7E359275'><pre id='7F7E359275'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-30 14:05:37 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：87196
                                  
                                    
          
                                   
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan.																									Courtesy Secrist family 
          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.
          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 
          advertisement
          “Oh, crap,” Secrist said to herself.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          STAT Report: Patient voices and perspectives
                                
                            
          Next article：  
                                      
                                          FDA approval of Sarepta Duchenne genetic therapy gives me hope
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles